Kodiak Sciences Inc (KOD): Price and Financial Metrics


Kodiak Sciences Inc (KOD): $6.92

0.20 (+2.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KOD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KOD Stock Price Chart Interactive Chart >

Price chart for KOD

KOD Price/Volume Stats

Current price $6.92 52-week high $26.39
Prev. close $6.72 52-week low $4.90
Day low $6.50 Volume 751,200
Day high $6.92 Avg. volume 2,127,946
50-day MA $6.79 Dividend yield N/A
200-day MA $14.38 Market Cap 359.52M

Kodiak Sciences Inc (KOD) Company Bio


Kodiak Sciences is a clinical stage biopharma specializing in therapeutics to treat chronic retinal diseases. The company was founded in 2005 and is based in New York City, New York.


KOD Latest News Stream


Event/Time News Detail
Loading, please wait...

KOD Latest Social Stream


Loading social stream, please wait...

View Full KOD Social Stream

Latest KOD News From Around the Web

Below are the latest news stories about Kodiak Sciences Inc that investors may wish to consider to help them evaluate KOD as an investment opportunity.

Kodiak sheds over $2B market cap after wet AMD setback for lead asset

Kodiak Sciences (KOD -79.8%), a clinical-stage biotech focused on eye diseases, has lost more than $2B of its market capitalization on Wednesday after the company said its lead asset KSI-301 did not meet the primary endpoint in a Phase 2b/3 trial for wet age-related macular degeneration. The 559-patient study was...

Seeking Alpha | February 23, 2022

KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?

Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session.

Chris MacDonald on InvestorPlace | February 23, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader!

William White on InvestorPlace | February 23, 2022

Peninsula biotech stock loses 80% after eye drug's late-stage study fails

The company — which still has a quartet of late-stage trials with the drug and more than $700 million in cash — saw its stock continue to drop on Thursday.

Yahoo | February 23, 2022

Why Kodiak Sciences Stock Is Cratering Today

What happened Shares of the clinical-stage biotech Kodiak Sciences (NASDAQ: KOD) are down by a hefty 80.3% as of 2:22 p.m. ET Wednesday afternoon. The drugmaker's stock is plunging today in response to its lead product candidate, KSI-301, failing to meet the primary endpoint of a combined phase 2/3 trial as a treatment for wet age-related macular degeneration (wet AMD).

Yahoo | February 23, 2022

Read More 'KOD' Stories Here

KOD Price Returns

1-mo 14.38%
3-mo -21.54%
6-mo -63.30%
1-year -58.62%
3-year 248.09%
5-year N/A
YTD -59.19%
2021 -42.29%
2020 104.18%
2019 913.38%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4945 seconds.